ReviewDiscover nano2026
Biomass derived carbon dots from green synthesis to multimodal bioimaging applications.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomass-derived carbon quantum dots (BCDs) have attracted considerable research attention as a novel category of sustainable fluorescent nanomaterials, attributed to their adjustable photoluminescence, superior biocompatibility, and eco-friendly synthesis methods. BCDs are made from renewable biomass sources like plants, algae, animal byproducts, and microorganisms, following the principles of green chemistry. This makes them much better for the environment and cheaper to make than carbon dots made in the traditional way. The field still has three big problems, though: the luminescence mechanism is still not well understood, with different pathways like carbon-core and surface-state emissions not having a single theoretical framework; optical modulation strategies are still not well developed, with quantum yields often falling below 30% and poor batch-to-batch consistency making it hard to standardize applications; and not enough is known about in vivo metabolic pathways and long-term toxicity to allow for systematic toxicological evaluation and clinical translation. The complex luminescence mechanisms, including carbon-core-state, surface-state, molecular-state, and cross-linked enhanced emission (CEE), are thoroughly examined to clarify the structure-property relationships that dictate their optical behavior. By using controlled synthesis and surface modification techniques, BCDs can be made to emit light in the visible to near-infrared (NIR) range. This makes them perfect for use in different types of multimodal imaging, such as single-photon, multi-photon, and photoacoustic bioimaging. Their natural ability to emit light, along with their low toxicity to cells and high stability in light, makes it possible to see cells and tissues in high detail. We talk more about the problems we are having right now with standardizing synthesis and controlling optical properties with precision. Future research should concentrate on refining reaction conditions and clarifying luminescence mechanisms to promote the clinical application of BCDs as next-generation, sustainable imaging agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.